
Discover Secrets of Long & Healthy Life to Improving the lives of people globally

Annual Report



2022



www.vivanzabiosciences.com



Mission:

We Pursue on our core Values and Collaborations with the team members and global partners that guide us in every decision making and we value such positive inputs to fine tune in providing our products and services.

Vision:

Constantly work towards ensuring quality medicines by finding solutions to the problems that are sustainable and lead to 'caring for better and meaningful life'.





What's inside

- 2 Vision Statement
- 4 Company Profile
- 9 Product Information
- 11 Notice
- 17 Explanatory Statements
- 23 Notes to Notice
- 29 Director's Report
- **36** Annexure-A (Certificate Stating Non-Applicability of Corporate Governance Report)
- 37 Annexure-B (FORM NO. MR-3)
- 42 Annexure-C (The Director's Report)
- **43** Annexure-D (Management Discussion And Analysis Report)
- 45 Annexure-E (FORM NO. AOC- 1)
- 47 Annexure-F (FORM NO. MGT 9)
- 55 Independent Auditor's Report (Standalone)
- 60 CARO Report
- 66 *Financial of the Company* (Standalone)
- 88 Independent Auditor's Report (Consolidated)
- 106 Financial of the Company (Consolidated)

What we do

Vivanza Biosciences Limited is a BSE-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines.

Vivanza Biosciences Limited has a 40years track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world.

A technology driven company, Vivanza Biosciences Limited has expertise in complex oral and topical dose forms including highly potent compounds, modified release products & injections.

Vivanza Biosciences Limited has two fullservice contract development, contract manufacturing.

For further information visit the Company's website at www.vivanzabiosciences.com

FY21-22 Key Metrics

₹ 1040.02 Lacs revenue

25+ pipeline products

60% marketed products globally

> 100+ contract

service clients

10,00,00,000 doses sold Globally



Our international footprint

Product development and manufacturing facility

UGANDA

36.1 acre facility; 126,000ft² of manufacturing space; 225,000ft² total facility.

Address : Plot-1, Bandali Close, Bugolobi, PO Box 264, Kampala, Uganda.

U.S.A. VENDOR

Successfully Procured the Manufacturing of Gainextra - 5% Minoxidil Topical Foam - Men Gainextra - 5% Minoxidil Topical Foam - Women

GHANA Dossier Under Registration

MALAWI Established Medical representative team in Malawi.

Mozambique Procured the order for Manufacturing of I.V. Bottles


Azerbaijan Establishing representative office 2022-23

Vivanza Biesciences Limited | Annual Report 2021-2022

Milestones

Year	Particulars	Country	Rationale
2022	Tie-up with vendor for manufacturing of Minoxidil		Manufacturing of Minoxidil
2022	Tie-up with USA based in license Injectable Products	Dominic Republic	Tablet / Injectable Medicines
2022	Licensing agreement with Vitaaglobal Healthcare Uganda Ltd.	UGANDA	Access to Injectable formulation.
2022	Licensing agreement with eight I.V. Products	Mozambique	Access to Southern African Countries.
2018	Acquired Vivanza Lifesciences Pvt. Ltd. (Formerly known as "Fortune Beverages Pvt Ltd")	India	Access to Food Supplements

SHAREHOLDING



Summary

Vivanza Biosciences Limited | Annual Report 2021-2022

BUSINESS MODEL

The business model involves four critical growth strategies to drive sustainable growth and achieve higher efficiencies. Vivanza Biosciences Limited is strategically poised to capitalise on the emerging opportunities in the global pharmaceutical sector, to deliver consistent long-term stakeholder value.



Growth Strategies

Create sustainable revenue streams

- Enhance share of specialty business globally
- Achieve differentiation by focusing on technically complex products
- Focus on key markets
- Focus on ROW market
- Ensure sustained compliance with global cGMP regulatory standards

Cost leadership

- Optimise operational costs
- Focus on vertically integrated operations
- Rationalise global manufacturing footprint


Business development

- Use and adopt new formulation.
- Focus on access to products, technology, market presence
- Focus on payback timelines

KEY PERFORMANCE INDICATORS


Gross Sales

(In **₹** Thousand)




Adjusted Net Profit After Minority Interests (excluding Exceptional Items)

(In **₹** Thousand)




Net Worth


(In **र** Thousand)



Z Vivanza Biosciences Limited I Annual Report 2021-2022



Adjusted Earnings Per Share (excluding Exceptional Items)



* EBITDA : Earnings before interest and tax



Vivanza Biosciences Limited | Annual Report 2021-2022

ANNUAL REPORT 2021 - 2022

BOARD OF DIRECTORS

Mr. Parikh H. A.	Director
Ms. Patel M. S.	Director
Mr. Bhatt G. B.	Managing Director
Mr. Shah S. D.	Director
Mr. Bhatt J. R.	Chief Financial Officer
Ms. Mashru A. J.	Company Secretary (Resigned w.e.f. 30.09.2021)
Mr. Bhojwani A. G.	Company Secretary (Appointed w.e.f. 27.05.2022)

AUDITORS

M/s. GM CA & Co. Chartered Accountants Ahmedabad

REGISTERED OFFICE

403/TF, Sarthik II, Opp. Rajpath Club, S.G Highway, Bodakdev, Ahmedabad

REGISTRAR & SHARE TRANSFER AGENTS

Purva Sharegistry (India) Pvt. Ltd. Shiv Shakti Industrial Estates, Unit No. 9 J. R. Boricha Marg, Opp. Kasturba Hospital Lane Lower Parel (E),Mumbai - 400011.